Tenon Medical (TNON) Earnings Date & Reports

Key Takeaways

• Third quarter 2026 revenue reached $1.4 million, up 22% year-over-year and 12% sequentially from the second quarter.
• Gross profit rose 23% to $1.0 million, with gross margin holding at a strong 66.3%.
• Loss from operations narrowed to $3.1 million, improving from $3.4 million in the prior-year quarter.
• Net loss widened to $6.6 million, or $5.39 per share, driven by non-cash warrant and debt-related expenses.
• Revenue and earnings per share (EPS) both came in below analyst consensus estimates for the quarter.
• Tenon ended the quarter with $8.3 million in cash and no outstanding debt after repaying its convertible notes.
• For more details on the ticker, you can explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• To discover data-driven trade ideas across the broader market, consider exploring Trending AI Robots.

Earnings Context and Why It Matters

Tenon Medical is a medical device company focused on sacro-pelvic disorders, anchored by its Catamaran SI (sacroiliac) joint fusion system and the Symmetry platform acquired through its SiVantage asset purchase. As a small, pre-profitability medtech name, each quarterly report carries outsized weight, because investors are watching whether commercial adoption and gross-margin execution can outpace a substantial operating-cost base. The company has delivered rapid top-line growth in recent quarters, yet profitability remains elusive, and capital raises have been a recurring theme. This report matters because it tests whether revenue momentum, margin stability, and balance-sheet actions are translating into a credible path toward reduced cash burn — the central concern for current and prospective shareholders.

Reported Results

For the third quarter ended September 30, 2026, Tenon Medical reported revenue of $1.4 million, a 22% increase from $1.2 million a year earlier and a 12% sequential gain. Gross profit was $1.0 million, up 23% year-over-year, with gross margin of 66.3% versus 65.9% in the prior-year period. Loss from operations improved to $3.1 million from $3.4 million. However, net loss widened to $6.6 million, or $5.39 per share, compared with $3.3 million, or $14.17 per share, a year ago. The larger net loss was primarily driven by non-cash items, including roughly $3.1 million of warrant inducement expense and about $0.7 million of non-cash interest tied to convertible notes that were repaid in full during the quarter. Both revenue and EPS fell short of analyst consensus estimates.

On the balance sheet, cash and cash equivalents stood at $8.3 million as of September 30, 2026, up from $3.8 million at the end of 2025. The company raised approximately $15.6 million in gross proceeds during the quarter and ended the period with no outstanding debt.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like TNON, it offers a structured way to identify comparable setups and emerging signals across the broader market.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around Tenon Medical remained pressured, with the stock down sharply over the trailing three- and twelve-month periods. The release did little to change that tone in the near term, as the top-line figure landed modestly below consensus expectations and the headline EPS loss came in weaker than anticipated. In after-hours trading following the announcement, shares edged lower. The market's interpretation appears balanced between two narratives: encouraging underlying growth and gross-margin stability on one hand, and continued cash burn plus dilution from repeated financing activity on the other. The non-cash nature of the largest swing factors in the net loss may temper some concern, but investors remain focused on whether operational losses can keep narrowing at the core level.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape how investors assess Tenon Medical. First is revenue durability. The company attributes growth to continued adoption of both the Catamaran and Symmetry platforms, so procedure-volume trends and the pace of new physician and distributor onboarding will be closely watched.

Second is gross-margin progression. Management has emphasized that margins should improve as higher revenue absorbs fixed production overhead, making any sustained move toward the low-to-mid 60% range or above a key indicator of operating leverage.

Third is cost discipline. Operating expenses remain elevated relative to the small revenue base, so investors will monitor whether spending growth stays below revenue growth. Fourth is the balance sheet and dilution risk. Although Tenon ended the quarter debt-free with a strengthened cash position, it relied on multiple financing transactions, and future capital raises could pressure the share count.

Finally, product-catalyst execution matters. The continued integration and rollout of the SiVantage assets, including the Symmetry Plus platform, represent near-term growth levers that could influence both revenue trajectory and investor confidence in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations